Jinfiniti Founder Dr. Jin-Xiong She: Building a Test-Intervene-Optimize Loop, Becoming a Global Anti-Aging Pioneer Within Six Years

Currently, in the field of life and health, humanity faces a major challenge: healthspan accounts for only a small proportion of overall human lifespan. Today, average life expectancy reaches around 80 years in many developed countries in Europe and the United States, as well as in China, Japan, and other nations. However, human healthspan—the period of life free from major age-related diseases—typically ends at approximately 50 to 55 years of age. Among individuals over 50, the majority suffer from one or multiple age-related conditions, such as cardiovascular diseases, cancer, and diabetes.

"The best way to narrow the significant gap between healthspan and lifespan is to prevent the onset of major diseases. 'By adopting scientific and correct approaches, nearly all diseases can be prevented, thereby extending both healthspan and overall longevity,' said Professor She Jinxiong, founder of Jinfiniti Precision Medicine. This has been the cause to which he has long devoted himself, and it remains his greatest vision for the rest of his life."

To realize this vision, he founded Jinfiniti Precision Medicine (Jinfeili Precision Medicine, hereinafter referred to as “Jinfiniti”). Currently, the company has become a global star enterprise in the anti-aging sector.Jinfiniti, established in 2018 and headquartered in Augusta, Georgia, USA, helps individuals address identified suboptimal health conditions, prevent age-related diseases, and extend healthspan by developing and analyzing unique, actionable biomarkers in conjunction with clinically validated interventions.

Recently, VCBeat conducted an exclusive interview with Professor She Jinxiong, Founder and CEO of Jinfiniti Precision Medicine., with the aim of gaining insight into Jinfiniti Precision Medicine’s anti-aging philosophy, technological expertise, business model, and future roadmap.

Professor Jin-Xiong She is a tenured professor at the Medical College of Georgia, Augusta University; Director of the Center for Biotechnology and Genomic Medicine; President of the American Society of Chinese Human Geneticists; and Chair of the Immunology, Transplantation, and Immunogenetics Committee of the American Diabetes Association.

He established the world’s largest and most comprehensive diabetes biobank and discovered multiple biomarkers for disease prediction and diagnosis.Furthermore, Professor She has published more than 400 peer-reviewed papers, with an H-index of 80 and over 22,000 citations, and has secured more than $100 million in research funding. In 2014, he was named one of the “Top 20 Medical Researchers in Georgia” by the Atlanta Business Chronicle.

Over the past four decades, Professor She’s primary research focus has been disease prevention. Through his research, he has come to deeply recognize the critical importance of early intervention in halting disease onset. Consequently, Professor She founded Jinfiniti, with the aspiration of translating his years of accumulated academic research into tools that serve public health.

Professor Jin-Xiong She and Dr. Bo-Ying Dun, his wife, co-founded Jinfiniti Precision Medicine

During this process, Jinfiniti Precision Medicine attracted the participation of numerous industry peers,The team has assembled numerous renowned experts, including Ronald Klatz, President of the American Academy of Anti-Aging Medicine (A4M), and Desmond Schatz, former President of the American Diabetes Association.Moreover, the majority of its members hold doctoral degrees and possess extensive research experience in clinical medicine and anti-aging. This has made Jinfiniti’s scientific research capabilities particularly prominent among anti-aging enterprises both domestically and internationally.

Specifically, Jinfiniti’s anti-aging philosophy is grounded in the Taoist concept of “Yin-Yang Balance,” known as “TAO.”

Jinfiniti’s Anti-Aging Philosophy

On one hand, “TAO” represents Jinfiniti’s core anti-aging measures: Test, Act, and Optimize.

“Currently, most anti-aging companies in the United States focus primarily on single interventions or products within the anti-aging sector, making it difficult to achieve optimal outcomes for anti-aging, which is a systemic engineering endeavor,” Professor She explained. Therefore, in terms of anti-aging philosophy,Jinfiniti is dedicated to providing systematic, holistic, and comprehensive anti-aging services.

The starting point of Jinfiniti’s anti-aging services is testing—first, by analyzing biomarkers to understand each individual’s health status, particularly their vulnerabilities, and then driving the anti-aging process with data. After a period of intervention, users undergo re-testing to determine the effectiveness of the measures and further optimize them accordingly. By organically integrating testing with intervention to create a closed loop of “test–intervene–retest–re-intervene,” Jinfiniti delivers precise, personalized anti-aging interventions tailored to individual differences and changes in health status.

On the other hand, in “TAO,” “Yin” and “Yang” respectively represent two major factors influencing aging: genetic/hereditary factors (Yin) and environmental/variable factors (Yang).

Among these factors, genes are inherited from one’s parents and remain largely unchanged throughout life. Moreover, the influence of genetics on lifespan is relatively limited, accounting for approximately 10%–20%. In contrast, environmental factors play a decisive role in human health and longevity. Professor She summarizes these factors into six categories: sleep, nutrition, physical exercise, personal lifestyle habits (such as smoking and excessive alcohol consumption), emotional and psychological well-being, and the broader living environment (including exposure to radiation and pollution).Professor She believes that only when these two Yin-Yang elements achieve balance can they exert a positive impact on human health, thereby achieving the goal of anti-aging.Therefore, Jinfiniti’s anti-aging interventions are precisely centered around the six controllable factors mentioned above.

Testing serves as the foundation and prerequisite for personalized interventions. Therefore, Jinfiniti places significant emphasis on the importance of testing for aging biomarkers, with NAD level assessment being one of the company’s core business offerings.

NAD is a coenzyme essential for over 500 different cellular activities. NAD optimization serves as the starting point for improving health and extending lifespan. Generally, after the age of 30, NAD levels decline to varying degrees in nearly everyone. However, individual NAD levels differ significantly. How much supplementation is appropriate? How can one determine the extent of the increase in NAD levels? This underscores the importance of NAD level testing.

Over the past two to three decades of development in the anti-aging industry, many companies have recognized the critical role of NAD testing in anti-aging interventions. Numerous enterprises have attempted to develop NAD testing methods suitable for consumer use, but have yet to succeed. The primary obstacle has been the extreme instability of NAD, which poses significant challenges to accurate detection.

Jinfiniti, however, has overcome this major challenge. The company has developed relevant technologies that can stabilize NAD after blood collection, preventing its rapid degradation. According to Professor She,Jinfiniti developed the world’s first at-home NAD test five years ago., and launched for consumers. In terms of testing methodology, Jinfiniti’s NAD level test utilizes finger-prick blood samples, offering a simple approach with a low operational threshold. Users can download detailed test reports along with corresponding intervention guidance from the company’s website.

Jinfiniti's NAD Level Testing

According to Professor She,Jinfiniti is the first company to develop NAD level testing capable of being deployed in large populations. To date, Jinfiniti holds approximately 95% of the global market share for NAD testing.

Moreover, Jinfiniti has established many data standards for NAD level testing, such as defining what constitutes healthy or deficient NAD levels. These standards have become the gold standard recognized and referenced by numerous companies within the industry. Additionally, Jinfiniti’s NAD level testing can evaluate the efficacy of other NAD supplements available on the market.

“Although general products can help increase NAD levels, we have found that many fail to bring individuals to optimal levels, so many consumers do not experience significant improvements in their physical condition,” explained Professor She. This is because, without the guidance of accurate data, NAD supplementation often results in either insufficient or excessive intake. Without testing NAD levels, it is difficult to determine precisely how to raise them to the optimal range.

Furthermore, there is significant variability in the efficacy of anti-aging products and services currently available on the market. The quality of some emerging anti-aging interventions still requires further evaluation. How to ensure that patients derive genuine benefit based on a comprehensive understanding of their own health status remains an urgent issue to be addressed.

To address this, Jinfiniti Precision Medicine conducts a baseline test before users begin taking supplement products, followed by a follow-up test after 3–4 weeks of use. By regularly monitoring biological markers before and after the intervention, the company ensures the safety and efficacy of product use to the greatest extent possible, addresses user trust issues, and drives a data-enabled precision anti-aging process.

Currently, epigenetic age testing is gaining significant traction. However, Professor She believes that, in terms of guiding anti-aging strategies, the assessment of functional aging biomarkers holds greater value. “While epigenetic clocks can reveal the discrepancy between one’s biological age and chronological age, they merely provide a data point and fail to offer a precise basis for determining anti-aging interventions.” Jinfiniti Precision Medicine places greater emphasis on testing indicators that can guide specific intervention measures, using the results to prioritize interventions accordingly.

Jinfiniti’s AgingSOS testing series is a prime example. This series utilizes a variety of unique biomarkers to help users identify subhealth issues and risk factors, guide anti-aging interventions, and evaluate their effectiveness. The series includes the Initial Testing Panel, the Advanced Testing Panel, and the Senescent Cells & NAD Testing Panel.

Among them,Initial Test PanelDetects 16 biomarkers, comprehensively covering six functional categories: nutrient deficiency disorders (NAD), cellular senescence, oxidative stress, inflammation, metabolic biomarkers, and tissue injury;Advanced PanelMeasure 22 biomarkers to assess mitochondrial dysfunction, cellular senescence, oxidative stress, inflammation, longevity hormones, metabolic status, micronutrients, DNA damage, and tissue damage;Senescent Cell and NAD Detection PanelDesigned specifically for clients seeking to evaluate the efficacy of their anti-aging regimens, this test detects intracellular NAD, senescence-associated β-galactosidase (β-gal), and four senescence-associated secretory phenotype (SASP) proteins.

There are numerous indicators within the human body that can guide anti-aging interventions, numbering at least in the hundreds or even thousands. How to select the minimal set of indicators while ensuring the provision of relatively comprehensive intervention information has become a major challenge in the field of aging biomarkers. “The more indicators tested, the higher the corresponding cost. Therefore, it is necessary to screen for the most instructive indicators and provide the maximum amount of anti-aging guidance with the fewest number of indicators,” explained Professor She.

Jinfiniti Precision Medicine can currently detect over 200 biomarkers, but the panels offered to customers typically include around 20 items, with plans to potentially expand this to 40–50 items in the future. This significant disparity between the total number of detectable biomarkers and those included in the panels is driven by considerations of cost-effectiveness and personalized intervention.Jinfiniti Precision Medicine combines various indicators into different packages based on the distinct health statuses of diverse populations, thereby meeting users’ needs for comprehensive health assessments as well as their personalized health requirements in specific areas., such as diabetes and cardiovascular diseases.

Meanwhile, the biomarker testing services offered by other U.S. companies typically consist of indicators already available in hospital settings. In contrast, Jinfiniti Precision Medicine provides many unique markers—particularly novel ones with significant guidance value for anti-aging interventions—that are not offered by competitors, such as NAD+ testing, cellular senescence, longevity hormones, and DNA damage assessment.

According to Professor She, companies in the field of aging biomarkers can currently be roughly divided into three categories:

First, testing involves conventional indicators currently recognized by the medical industry, with the primary challenge lying in the business model due to low barriers to entry;

Second, the field of biological age testing, particularly the development of epigenetic clocks, has become relatively crowded, leaving limited room for innovative breakthroughs;

Third, develop and detect new biomarkers. Among these, certain key indicators that provide significant guidance on health and aging status are extremely challenging to measure. Companies lacking exceptional R&D capabilities in detection technologies will find it difficult to enter this niche sector. “First, this requires a profound understanding of which biomarkers offer substantial guidance for anti-aging and disease prevention, which in itself is highly challenging. Furthermore, after identifying these biomarkers, companies must develop detection methods that can be practically implemented in the market, creating another barrier to entry in this field.”

As a global leader in this sector, Jinfiniti has developed four to five new biomarkers and introduced them to the market. For instance, addressing menopause—a prevalent women’s health concern—Jinfiniti has identified three to four novel risk indicators with significant impact on menopause, holding substantial importance for the treatment of perimenopausal and menopause-related conditions.

“As a research-driven company committed to original innovation, Jinfiniti is continuously developing biomarkers at the forefront of anti-aging, backed by robust technical capabilities that support our R&D and scientific translation,” pointed out Professor She, highlighting this as one of Jinfiniti’s core strengths.

In the realm of supplements, Jinfiniti has developed the Jinfiniti Vitality NAD supplement. Generally, most existing supplements on the market can only elevate NAD levels through a single pathway, whereasJinfiniti Vitality NAD Supplement Features an Exclusive, Clinically Validated, First-of-Its-Kind, Patent-Pending Formula, including NAD precursors, creatine monohydrate, D-ribose, and nicotinamide, can elevate NAD levels through three distinct pathways and exert synergistic effects.

Jinfiniti Vitality NAD Supplement

This formula has been extensively tested in clinical studies, across hundreds of clinics, and among tens of thousands of consumers, demonstrating significantly superior efficacy compared to other brands’ pure NAD precursors. Furthermore, nearly all users who optimized their NAD levels experienced functional and clinical improvements in health and performance. “And,"Our product can help approximately 90% of users optimize their NAD levels, whereas most products on the market achieve this for only 20% to 30% of users.".” Professor She added.

In addition, compared with existing products on the market, Jinfiniti Vitality NAD supplements can bring more functional improvements, such as increasing energy and sleep quality, reducing inflammation, muscle and joint pain, alleviating allergy and asthma symptoms, improving mental clarity, and ameliorating dementia symptoms.

Professor She believes that the anti-aging industry is still in its nascent stage and will experience explosive growth within the next three to five years. The gap between the Chinese and U.S. markets is relatively small, with China rapidly catching up in many niche segments.

Currently, from a governmental perspective, most governments have not yet truly placed this issue on their agendas. However, there is good reason to believe that governments worldwide will soon fully recognize the importance of anti-aging. This is not only because anti-aging interventions can enhance individuals’ health status and extend lifespan, but also because, from an economic standpoint, they can reduce national healthcare expenditures, thereby generating significant economic benefits and broad social benefits. Consequently, the development prospects of the anti-aging industry are almost beyond doubt.

In the anti-aging industry, Jinfiniti positions itself primarily as a technology service provider and partner within the industrial ecosystem. “The challenge of aging cannot be addressed by any single company acting alone; it requires collaborative efforts among enterprises. We provide advanced technological solutions to anti-aging companies, helping enhance the efficacy of their products and services, while jointly exploring more effective anti-aging approaches,” explained Professor She. It is precisely for this reason that businesses seeking collaboration with Jinfiniti continue to flow in steadily.

Currently,Jinfiniti has served over 50,000 individuals, covering more than 60 countries and regions including the United States, Canada, the United Kingdom, and Australia. Furthermore, Jinfiniti is highly interested in the Chinese market.“We hope to explore the application potential of combining traditional Chinese medicine theory with modern biological methods in China, and develop novel anti-aging interventions,” said Professor She.

In the future, Jinfiniti will focus primarily on the research and development of its products and services, continuing to deepen its expertise in the development of aging biomarkers and innovation in anti-aging supplements. By collaborating with other enterprises across the industry chain, Jinfiniti aims to make high-quality disease prevention and anti-aging services accessible to a broader user base, thereby driving innovation and development in the global anti-aging industry.